National Institutes of Health logo

NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)

National Institutes of Health

Funding Amount

Not stated

Deadline

November 16, 2029

1138 days left

Grant Type

Federal

Can we apply?

Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.

Eligible organizations

  • For-profit businesses
  • County governments
  • School districts
  • Public colleges & universities
  • City & township governments
  • Tribal governments
  • Private colleges & universities
  • Nonprofits (501(c)(3))

Geography

  • Public Housing Authorities/Indian Housing AuthoritiesFaith-based or Community-based Organizations.

Other requirements

  • Other Eligible Applicants.
  • Regional Organizations

Overview

The purpose of NEI’s Translational Research program is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. The TRP will support the product development of biological, pharmaceutical, medical device, and/or combination therapies for any disease or disorder of the visual system. The TRP will utilize a bi-phasic, milestone-driven mechanism of award. The R61 phase can be up to two years and will support research that has demonstrated significant preliminary data but has not advanced to the level of clinical translation. The R33 phase can be up to three years and will support research that is in the final states of preclinical development with potential for near-term clinical development. The R33 is to focus on advancing a single therapeutic candidate through Investigational New Drug or Investigational Device Exemption (IND/IDE) enabling studies, filing an IND/IDE package with the FDA, and designing future clinical trials. R33 recipients must submit or obtain an IND/IDE application to FDA, or must transition the product to clinical practice, within the period of performance. The specific activities appropriate for the R33 phase will depend on the product under study and available preliminary data on the product. Delineation of milestones by the applicant for the R61 and R33 phases is a key characteristic of this program. A milestone is defined as a scheduled event in the project timeline that signifies the completion of a major project stage or activity. This program will support applications that propose a series of milestones including manufacturing and product development goals. Applications that address contingency plans to proactively confront potential delays in meeting the milestones are strongly encouraged. Milestones are required for both phases. Milestones must be specific, measurable, achievable, relevant, and time-bound (SMART). Mature efforts that

Details

  • Agency: National Institutes of Health
  • Department: Department of Health and Human Services
  • Opportunity #: PAR-26-073
  • Expected Awards: 5
  • Instrument: grant

Eligibility

Other Eligible ApplicantsIndependent School DistrictsPublic Housing Authorities/Indian Housing AuthoritiesFaith-based or Community-based OrganizationsRegional Organizations

Focus Areas & Funding Uses

Fields of Work

  • Science research
  • Hearing and vision

Categories

Browse similar grants by category

Related Grants

Open grants from this funder and similar programs

Your AI grants department

Ready to apply for NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)?

Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.

You found NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed). Now let's win it.

Start writing